Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilvadipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F known ✓ | O60840 | 2/20 | 0.60 |
| ▸ | CACNA1D known ✓ | Q01668 | 2/20 | 0.60 |
| ▸ | CACNA1S known ✓ | Q13698 | 2/20 | 0.60 |
| ▸ | CACNA1C known ✓ | Q13936 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilvadipine SCHEMBL11913265 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL30875962 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL8004036 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL6044973 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL33730 | 1.00 | ADORA3 (1.00) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| SCHEMBL7380227 | 0.94 | ADORA3 (0.89) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL8170123 | 0.94 | ADORA3 (0.88) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL1538947 | 0.93 | ADORA3 (0.87) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| Nilvadipine SCHEMBL7625807 | 0.93 | ADORA3 (0.85) | ADORA3NR1I2NR3C1ABCB1TBXA2R | |
| SCHEMBL30357961 | 0.90 | ADORA3 (0.81) | ADORA3NR1I2NR3C1ABCB1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15408 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107412-A1 | SARCOSPAN MODULATION AND METHODS OF MEAT AND TISSUE CULTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4648769-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2025-11-19 | — | — | EP | claimed |
| US-20250345332-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-13 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-20250177493-A1 | TOPICAL THERAPEUTIC FORMULATIONS | HYBRID MEDICAL, LLC | 2025-06-05 | — | — | US | claimed |
| EP-3801510-B1 | COMPOUNDS INCREASING THE EXPRESSION OF SARCOSPAN FOR USE IN THE TREATMENT OF MUSCULAR DYSTROPHY | UNIV CALIFORNIA (US) | 2025-04-23 | — | — | EP | claimed |
| EP-4529461-A1 | APROCITENTAN FOR THE TREATMENT OF HYPERTENSION | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-02 | — | — | EP | claimed |
| US-20250090501-A1 | METHODS OF TREATING GUT MOTILITY DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-20 | — | — | US | claimed |
| EP-0319983-A1 | Association of pyrimidine derivatives and calcium antagonists to induce and stimulate the hair growth and to reduce hair loss | L'OREAL (FR) | 1989-06-14 | — | — | EP | claimed |
| EP-0317780-A1 | Sustained (controlled) release delivery system for substituted dihydropyridine calcium channel blockers | AMERICAN CYANAMID COMPANY (US) | 1989-05-31 | — | — | EP | claimed |
| US-4820720-A | GLYCEROL MONOLAURATE AND ETHANOL ENHANCERS;CONTROLLED DRUG DELIVERY | ALZA CORPORATION (US) | 1989-04-11 | — | — | US | claimed |
| EP-0305026-A2 | Transdermal drug delivery device with dual permeation enhancers | ALZA CORPORATION (US) | 1989-03-01 | — | — | EP | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0296553-A2 | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-12-28 | — | — | EP | claimed |
| EP-0294601-A2 | Transdermal delivery of pharmaceuticals | AMERICAN CYANAMID COMPANY (US) | 1988-12-14 | — | — | EP | claimed |
| US-4764379-A | ETHANOL AND GLYCEROL MONOLAURATE | ALZA CORPORATION (US) | 1988-08-16 | — | — | US | claimed |
| EP-0237506-A1 | Pharmaceutical composition | LEJUS MEDICAL AKTIEBOLAG (SE) | 1987-09-16 | — | — | EP | claimed |
| US-4338322-A | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-07-06 | — | — | US | claimed |